# Therapeutic Magnetic Fields in Oncology: A Systematic Review of Safety and Supportive Clinical Use

**Authors:** Saverio Colonna, Fabio Casacci

PMC · DOI: 10.7759/cureus.101970 · Cureus · 2026-01-21

## TL;DR

This paper reviews the safety and use of therapeutic magnetic fields in cancer patients, finding no evidence of harm and potential benefits for symptom management.

## Contribution

The paper challenges the assumption that magnetic fields are harmful in oncology and identifies a need for more clinical trials.

## Key findings

- No evidence of disease progression or treatment impairment from magnetic field exposure in cancer patients.
- Magnetic fields may improve chemotherapy-induced neuropathy and quality of life in cancer patients.
- Observational evidence suggests benefits for pain and rehabilitation in cancer remission.

## Abstract

Therapeutic magnetic fields are widely used in rehabilitation and physiotherapy for musculoskeletal and neurological conditions. However, their use in oncological patients has historically been approached with caution and is often considered contraindicated, despite limited clinical evidence supporting this concern.

A systematic review was conducted in accordance with PRISMA guidelines. PubMed/MEDLINE was searched for studies evaluating therapeutic magnetic fields in oncological populations. Studies were classified according to predefined research questions addressing oncological safety, supportive care during cancer treatment, and management of comorbidities. Study selection, data extraction, and qualitative synthesis were performed.

A total of 3,841 records were identified. Only one randomized controlled trial specifically assessed oncological safety outcomes and found no evidence of disease progression, reduced survival, or impaired treatment response associated with magnetic field exposure. A larger body of heterogeneous evidence evaluated magnetic fields as supportive interventions during oncological treatments, particularly for chemotherapy-induced peripheral neuropathy, quality of life, and symptom burden. These studies reported improvements in neurotoxicity, patient-reported outcomes, and treatment tolerability, although methodological limitations were common. Evidence regarding pain management and rehabilitation in oncological remission was predominantly observational.

Current evidence does not support the assumption that therapeutic magnetic fields are inherently harmful in oncological patients. While data on oncological safety remain limited, available studies do not indicate adverse oncological outcomes. Magnetic field therapy may represent a feasible supportive intervention for symptom management and rehabilitation in selected oncological populations. However, well-designed prospective trials are required to better define safety profiles, clinical efficacy, and appropriate indications.

## Full-text entities

- **Diseases:** neuropathies (MESH:D009422), oncological (MESH:D000072716), hepatocellular carcinoma (MESH:D006528), ovarian cancer (MESH:D010051), CIPN (MESH:D010523), neuropathic pain (MESH:D009437), Musculoskeletal Comorbidities (MESH:D009140), NCV (MESH:C564269), joint stiffness (MESH:C535724), bone sarcoma (MESH:D001847), hip and knee osteoarthritis (MESH:D020370), toxicity (MESH:D064420), sensory ataxia (MESH:D001259), carcinogenic (MESH:D011230), bone metastases (MESH:D009362), non-small cell lung cancer (MESH:D002289), chronic low back pain (MESH:D017116), renal cancer (MESH:D007680), peroneal nerve (MESH:D020427), neurological (MESH:D009461), osteoarthritis (MESH:D010003), functional disorders (MESH:D003291), musculoskeletal pain disorders (MESH:D059352), spinal stenosis (MESH:D013130), lymphedema (MESH:D008209), neuropathic symptoms (MESH:D001750), Cancer (MESH:D009369), lung cancer (MESH:D008175), neurotoxicity (MESH:D020258), pain (MESH:D010146), mastectomy (MESH:D000072656), melanoma (MESH:D008545), degenerative joint diseases (MESH:D019636), osteosarcoma (MESH:D012516), inflammatory (MESH:D007249)
- **Chemicals:** adriamycin (MESH:D004317)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12921648/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12921648/full.md

## References

64 references — full list in the complete paper: https://tomesphere.com/paper/PMC12921648/full.md

---
Source: https://tomesphere.com/paper/PMC12921648